Mitochondrial Dysfunction Driven by MARylation of GLUD1 as a Key Barrier to Sorafenib‐Induced Ferroptosis in Hepatocellular Carcinoma
Advanced Science · 15.11.2026
DOI: 10.1002/advs.78574 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 15.11.2026. Verfasst von Kangnan Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Research Grants Council of Hong Kong.
Abstract (Originalsprache)
Restriction to Sorafenib‐induced ferroptosis in hepatocellular carcinoma (HCC) involves poorly understood mitochondrial dysfunction. Using biochemical assays, orthotopic and patient‐derived xenograft (PDX) models, and clinical microarrays, we discover that Sorafenib triggers a metabolic self‐limiting effect. Mechanistically, Sorafenib inhibits mTOR to upregulate SIRT4, which mono‐ADP‐ribosylates (MARylates) GLUD1 at arginine 60 (R60), suppressing its enzymatic activity. Concurrently, mitophagy recruits MARylated GLUD1 to lysosomes, where the E3 ligase DTX3L specifically recognizes the modification via its DTC domain. DTX3L then non‐canonically ubiquitinates the 3′‐hydroxyl group of the ADP‐ribose moiety, driving GLUD1 proteasomal degradation. This dual suppression specifically blocks glutamate‐to‐α‐ketoglutarate (α‐KG) conversion, starving the TCA cycle and impairing Electron Transport Chain (ETC) activity, thereby preventing lipid peroxidation. Clinically, the GLUD1/SIRT4 expression profile predicts relapse‐free survival in HCC patients. Crucially, bypassing this blockade via α‐KG supplementation refuels the TCA cycle and restores ETC‐driven lipid ROS generation, yielding profound synergistic benefits with Sorafenib, particularly in PDX models with low GLUD1 enzymatic activity. Thus, R60 MARylation of GLUD1 constitutes a critical barrier to Sorafenib‐induced ferroptosis. Targeting this mTOR/SIRT4/DTX3L cascade or replenishing α‐KG represents a promising precision strategy to overcome Sorafenib resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Department of Gastroenterology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
- Department of Clinical laboratory, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, China.
- Hanyu Biomed Center, Shanghai Hanyu Biomedicine Technology Co., Ltd., Shanghai, China.
- Department of Biomedical Sciences, College of Biomedicine, City University of Hong Kong, Hong Kong, China.
ORCID-Profile: Kangnan Zhang, Bin Liu, Lingxi Chen, Hao Chang, Ling Xu
Förderung
- National Natural Science Foundation of China
- Research Grants Council of Hong Kong
Zitieren
APA
Zhang, K., Mo, W., Han, J., Xiang, S., Zhang, Q., Liu, B., Yu, Q., Chen, L., Chang, H., & Xu, L. (2026). Mitochondrial Dysfunction Driven by MARylation of GLUD1 as a Key Barrier to Sorafenib‐Induced Ferroptosis in Hepatocellular Carcinoma. Advanced Science. https://doi.org/10.1002/advs.78574
Vancouver
Zhang K, Mo W, Han J, Xiang S, Zhang Q, Liu B, et al. Mitochondrial Dysfunction Driven by MARylation of GLUD1 as a Key Barrier to Sorafenib‐Induced Ferroptosis in Hepatocellular Carcinoma. Advanced Science. 2026. doi:10.1002/advs.78574
BibTeX
@article{Zhang2026,
author = {Zhang, Kangnan and Mo, Wenhui and Han, Jinlu and Xiang, Shihao and Zhang, Qinghui and Liu, Bin and Yu, Qin and Chen, Lingxi and Chang, Hao and Xu, Ling},
title = {Mitochondrial Dysfunction Driven by MARylation of GLUD1 as a Key Barrier to Sorafenib‐Induced Ferroptosis in Hepatocellular Carcinoma},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.78574}
}
EUVIMED